Therapeutic strategies that include drugs that inhibit HIF-1α protein accumulation [19, 20, 28] or perhaps TAZ target gene products [29] may improve outcome in women with triple negative breast cancer, who are currently treated with cytotoxic chemotherapy with durable response rates of less than 20%. This evidence concerns the gene HIF1A and triple-negative breast carcinoma.